Max Mendez

Publications

• Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
• HIV Protease Inhibitors for the Treatment of Multiple Myeloma
• A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
• Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia
• Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease
• ARTÍCULO ORIGINAL: VALORACIÓN RÁPIDA DEL RIESGO TROMBÓTICO EN PACIENTES HOSPITALIZADOS CON ENFERMEDADES NO QUIRÚRGICAS
• TEMA 17-2014: LA VÍA DE CONTACTO: ¿EL FUTURO DE LOS ANTICOAGULANTES?
• Molecular analysis of FVIII gene in severe HA patients of Costa Rica
• Graft Failure Following Allogeneic Stem Cell Transplantation for Primary Myelofibrosis: A Case Report
• Molecular analysis of FVIII gene in severe HA patients of Costa Rica: Prevalence of intron 1 and 22 inversion
• FREQUENCY AND GENOMIC ASPECTS OF INTRINSIC RESISTANCE TO VISMODEGIB IN LOCALLY ADVANCED BASAL CELL CARCINOMA
• Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
• HIV protease inhibitors for the treatment of multiple myeloma.
• Haemovigilance Annual Report 2021
• High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex